FUSN 21.55 (+0%)
CA36118A1003BiotechnologyBiotechnology

Fusion Pharmaceuticals (FUSN) Stock Highlights

21.55 | +0%
2024-12-21 03:41:25
Fusion Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing alpha therapeutics for curing cancer. It develops Targeted Alpha Therapies (TAT) together with its proprietary Fast-Clear linker technology. The firms lead product candidate comprises FPI-1434, a monotherapy for the treatment of a variety of cancers; FPI-1966, for the treatment of head and neck and bladder cancers; and FPI-2059 among others.

Statistics

Range Today
21.55 21.55
Volume Today 0
Range 1 Year
2.31 21.6
Volume 1 Year 217.04M
Range 3 Year
1.98 21.6
Volume 3 Year 264.77M
Range 10 Year
1.98 21.6
Volume 10 Year 287.16M

Highlights

Market Capitalization 1.83B (small)
Floating Shares 61.58M
Current Price 21.55
Price To Earnings 0
Price To Revenue 826.99
Price To Book 7.56
Earnings Per Share -1.4
Payout Ratio 0%

Performance

Latest 0%
1 Month +0.47%
3 Months +73.79%
6 Months +298.34%
1 Year +335.35%
3 Years +159.64%
5 Years +16.49%
10 Years +16.49%

Benchmarks


Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.